Modeling the PAX5P80R Mutation Reveals HIF2α Activation as a Common Feature and Therapeutic Target in B-cell Acute...

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• The transcription factor PAX5 is frequently altered in B-cell acute lymphoblastic leukemia (B-ALL).
• The PAX5 P80R mutation is the most common PAX5 point mutation in B-ALL, defining a distinct subtype with a unique transcriptional program.
• Understanding the mechanism of PAX5P80R in B-ALL pathogenesis is crucial for developing targeted therapies.

Purpose of the Study:

• To develop a model system to investigate how the PAX5 P80R mutation disrupts normal B-cell differentiation.
• To identify the oncogenic pathways involved in PAX5P80R-driven B-ALL progression.
• To explore potential therapeutic strategies targeting PAX5P80R-driven B-ALL.

Main Methods:

• Utilized a retroviral complementation approach in Pax5-deficient murine fetal liver cells.
• Performed functional and molecular analyses to assess B-cell commitment and T-cell development.
• Employed transplantation models to study clonal B-ALL transformation.
• Conducted transcriptomic analyses and pharmacological investigations.

Main Results:

• PAX5P80R failed to rescue B-cell commitment but maintained T-cell repression in a murine model.
• PAX5P80R-driven B-ALL transformation occurred through secondary mutations in JAK/STAT and RAS/MAPK pathways.
• Ectopic activation of HIF2α was identified as a common feature in B-ALL.
• Acriflavine demonstrated potent efficacy against B-ALL in vitro.

Conclusions:

• The study successfully modeled the multistep process of B-ALL driven by the PAX5 P80R mutation.
• PAX5P80R perturbs B-cell differentiation and cooperates with mutations in key signaling pathways for leukemogenesis.
• Ectopic HIF2α activation is a significant finding in B-ALL, and acriflavine represents a promising therapeutic agent.